PORTSMOUTH, N.H., Sept. 11, 2025 /PRNewswire/ -- Laborie Medical Technologies Corp., a global leader in medical technology, today announced the appointment of Chris Smith as Chief Executive Officer, effective September 22, 2025. Smith succeeds Michael Frazzette, who announced his retirement last month. Chris Smith brings over three decades of executive leadership experience in the healthcare and medical technology sectors. He has previously served as CEO of NeoGenomics Laboratories, Ortho Clinical Diagnostics, and Cochlear Limited, where he led transformative growth and innovation. Smith has also held several board positions across both private and public companies. "The Laborie Board of Directors thanks Mike for his outstanding contributions to Laborie during his tenure as CEO," said David Perez, Chair of the Board. "We look forward to working with Chris as Laborie's new CEO, and we are confident that his experience and expertise make him the right leader to guide Laborie's next chapter." "We look forward to working with Mike in his new capacity and thank him for his exceptional leadership of Laborie and partnership with Patricia Industries over the past eight years," said Yuriy Prilutskiy, Co-Head of Patricia Industries. "During this time, Laborie has achieved significant growth, expanded its product portfolio and global presence, and fostered an innovative, high-performance culture. We are excited to partner with Chris to build on this momentum, and are confident that his leadership style, business acumen, and deep expertise in medical technology will position him to lead Laborie with impact and vision." Smith has served on Laborie's Board of Directors since 2023, providing strategic counsel during a period of significant expansion. His familiarity with the company's mission and operations positions him to seamlessly transition into the CEO role. "Laborie's mission truly resonates with me, and I'm excited to work with such an exceptional team as we continue to drive innovation and enhance patient lives in our three leading platforms: urology, gastroenterology and OB." said Smith. Laborie will host welcome sessions in the coming weeks to introduce Smith to employees and partners across its global network. About Laborie Medical Technologies Headquartered in Portsmouth, New Hampshire, Laborie is a global medical technology company focused on Urology, Urogynecology, Gastroenterology, Obstetrics, Gynecology & Neonatal Health. We manufacture and deliver high-quality, high-impact diagnostic and therapeutic products that help clinicians and hospitals preserve and restore patient dignity. Clinicians and hospitals look to us as the market-leading experts in our business segments, and we support our products with a world-class clinical education & information program. Laborie is a portfolio company of Patricia Industries. For more information visit www.laborie.com. Story Continues About Patricia Industries Patricia Industries is a long-term owner that invests in companies and works to develop each company to its full potential. Patricia Industries is a part of the industrial holding company Investor AB, whose main owner is the Wallenberg Foundations.Cision View original content:https://www.prnewswire.com/news-releases/laborie-appoints-chris-smith-as-chief-executive-officer-302553310.html View Comments
Laborie Appoints Chris Smith as Chief Executive Officer
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...